• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Pediatr . Factors Associated with Antiviral Drug Use among Commercially Insured Children at High Risk for Complications of Influenza

tetano

Editor, Senior Moderator
J Pediatr


. 2025 Apr 2:114574.
doi: 10.1016/j.jpeds.2025.114574. Online ahead of print. Factors Associated with Antiviral Drug Use among Commercially Insured Children at High Risk for Complications of Influenza

Abdullah Abdelaziz[SUP] 1 [/SUP], Jyotirmoy Sarker[SUP] 1 [/SUP], Pei-Wen Lien[SUP] 1 [/SUP], Derek J Williams[SUP] 2 [/SUP], Carlos G Grijalva[SUP] 3 [/SUP], Todd A Lee[SUP] 1 [/SUP], James W Antoon[SUP] 4 [/SUP]



Affiliations
Free article Abstract

Objectives: To evaluate the prevalence of antiviral drug use in US children with influenza at high risk for complications and to identify factors associated with dispensing.
Study design: We conducted a retrospective cohort study of outpatient visits for individuals < 18 years during the 2016-2020 influenza seasons using the Merative MarketScan Commercial Claims and Encounter database. High-risk status was defined using Infectious Disease Society of America definitions and included: age, specific co-morbidities, pregnancy or post-partum status, and living in a long-term care facility. The primary outcome was antiviral (oseltamivir, zanamivir, baloxavir) dispensing within two days of influenza diagnosis. We determined clinical factors associated with antiviral dispensing using modified Poisson regression.
Results: A total of 372,372 influenza episodes were identified among 331,389 children at high risk for influenza complications and included in this study. The median (interquartile range) age was 4.0 years (2.0, 9.0). Overall, during 201,638 (54.1%) episodes of the influenza, antiviral treatment was dispensed. Factors associated with increased antiviral use included asthma, West and South US geographic regions, urgent care settings, and specific health insurance plans. Factors associated with decreased antiviral use include younger age, emergency department setting, Midwest and Northeast geographic regions, and health insurance plans.
Conclusion: Despite national guidelines recommending that all children at high risk for influenza complications receive antiviral treatment, nearly half of these children at high-risk did not receive an antiviral in our study. We identify several factors associated with decreased antiviral treatment that may serve to inform future interventions aiming to improve the care of vulnerable children with influenza.

Keywords: antiviral; baloxavir; influenza; oseltamivir; pediatrics.

 
Back
Top